Can a vitamin a-like drug shield immune cells during cancer radiation?

NCT ID NCT06439888

Recruiting now Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Dec 10, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tests whether adding a drug called ATRA (related to vitamin A) to targeted radiation therapy can prevent a drop in infection-fighting white blood cells (lymphocytes) in adults with solid tumors that have spread to a few spots. About 58 participants will receive radiation to all visible tumors, with or without ATRA. The goal is to see if the combination is safe and helps maintain immune cell levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Léon Bérard
NOT_YET_RECRUITING

Lyon, 69000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Gustave Roussy
RECRUITING

Villejuif, 94800, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

OLIGOMETASTATIC DISEASE SOLID TUMOR, ADULT